{"nctId":"NCT02085252","briefTitle":"A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer","startDateStruct":{"date":"2013-06-03","type":"ACTUAL"},"conditions":["Prostate Cancer"],"count":116,"armGroups":[{"label":"Leuprorelin 11.25 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Leuprorelin","Drug: Bicalutamide"]},{"label":"Active surveillance","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Leuprorelin","otherNames":["Enantone ®"]},{"name":"Bicalutamide","otherNames":["Casodex ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Is an out-patient 50 to 80 years old.\n2. Has read, understood, signed and dated the informed consent.\n3. Has indolent prostate cancer defined by:\n\n   * Clinical Stage T1c or T2a.\n   * Biopsy cores of which at least 12 reveal the presence of positive cores and the absence of cores with tumor length \\> 3 mm.\n   * Absence of Grade 4 cells (Gleason \\<7).\n   * Prostate specific antigen (PSA) levels \\<10 ng/ml.\n4. Has a life expectancy \\> 5 years.\n5. Has accepted the principle of active surveillance.\n6. Is willing to participate in the study for a minimum of fifteen months.\n\nExclusion Criteria:\n\n1. Has prior androgen deprivation including a 5-alpha reductase inhibitor (finasteride or dutasteride) within the last 6 months.\n2. Has psychological failure related to prostate cancer therapy.\n3. Has any active disorder likely to affect the conduct of the study or the patient's prognosis during the study.\n4. Has a mental deficiency or any other reason that may hinder the understanding or strict application of the protocol.\n5. Is under judicial protection, tutorship or curatorship.\n6. Is unlikely to attend control visits.\n7. Is currently enrolled in an investigational study or has participated in another investigational study within the last 3 months.\n8. Has an allergy or hypersensitivity to any components of leuprorelin (Enantone LP) 11.25 mg or Casodex® 50 mg.\n9. Has a medical history of severely impaired hepatic function linked to bicalutamide or a pathological cause.\n10. Has testosterone level \\< 0.5 ng/ml.","healthyVolunteers":false,"sex":"MALE","minimumAge":"50 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Negative Biopsies at Month 12","description":"Staging biopsy of at least 12 cores were sampled and analyzed according to a centralized biopsy procedure which confirm the results of the first biopsy \\[presence of positive cores, the absence of core with tumor length \\> 3 millimeters (mm), and absence Grade 4 cells (Gleason score \\< 7)\\]. The Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Gleason Score ≥ 7","description":"Gleason score grades prostate cancer tissue, based on its appearance under a microscope. Scores range from 2 to 10, with a higher score meaning that the cancer tissue is more likely to spread.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the International Prostate Symptom Score (I-PSS) Total Symptom (S) Score","description":"The I-PSS is an 8-question tool used to measure prostate symptoms (≤7: mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic). The first 7 symptom questions answered on a scale of 0 (never) to 5 (almost always) are used to determine the I-PSS Total S Score for a total possible score of 0 to 35. The 8th question is quality of life and is not reported here. A negative change from baseline indicates improvement. An Analysis of Covariance (ANCOVA) model fitted with baseline I-PSS total score and age as covariates was used for analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":null},{"groupId":"OG001","value":"1.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":null},{"groupId":"OG001","value":"0.32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.13","spread":null},{"groupId":"OG001","value":"0.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.48","spread":null},{"groupId":"OG001","value":"0.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Prostatic Volume as a Measure of Tumor Radiologic Progression Using Dynamic Magnetic Resonance Imaging (MRI)","description":"MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to calculate the prostatic volume in cubic millimeters (mm\\^3).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.48","spread":"25.09"},{"groupId":"OG001","value":"49.44","spread":"25.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.47","spread":"28.15"},{"groupId":"OG001","value":"48.33","spread":"20.18"}]}]}]},{"type":"SECONDARY","title":"Highest Diameter of the Lesion as a Measure of Tumor Radiologic Progression Using Dynamic MRI","description":"MRI is an imaging technique used to investigate the anatomy and function of the body. Measurements were taken to determine the diameter of the lesions in millimeters (mm).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.39","spread":"2.80"},{"groupId":"OG001","value":"7.78","spread":"2.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.25","spread":"3.62"},{"groupId":"OG001","value":"7.69","spread":"2.56"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Prostate-specific Antigen (PSA) Levels","description":"Blood was collected and sent to a central laboratory for analysis of PSA reported in milligrams/milliliter (mg/mL). A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline PSA Level and age as covariates was used for analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.61","spread":null},{"groupId":"OG001","value":"0.22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.27","spread":null},{"groupId":"OG001","value":"0.85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.46","spread":null},{"groupId":"OG001","value":"0.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.76","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Score","description":"The HADS is a 14-item scale that measures anxiety (7-items) and depression (7-items) over the previous week. Each question is answered on a scale of 0 (best) to 3 (worst) for a total possible score of 0 to 42, with higher scores indicating more anxiety and depression. A negative change from baseline indicates improvement. An ANCOVA model fitted with baseline HADS score and age as covariates was used for analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":null},{"groupId":"OG001","value":"-1.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":null},{"groupId":"OG001","value":"-1.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.06","spread":null},{"groupId":"OG001","value":"-1.76","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.87","spread":null},{"groupId":"OG001","value":"-1.95","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the International Index of Erectile Function (IIEF-5) Questionnaire Score","description":"The IIEF-5, a 5 question patient completed questionnaire, is a measure of erectile dysfunction over the past 6 months. Each question is answered on a scale of 1 (worst) to 5 (best). Total score ranges from 5 to 25 with higher scores indicating better function (5-7: severe; 8-11: moderate; 12-16: mild to moderate;17-21: mild; 22-25: none). A positive change from baseline indicates improvement. A negative change from baseline indicates a worsening. An ANCOVA model fitted with baseline IIEF-5 score and age as covariates was used for analyses.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.40","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.87","spread":null},{"groupId":"OG001","value":"0.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.94","spread":null},{"groupId":"OG001","value":"-0.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":null},{"groupId":"OG001","value":"-0.02","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":58},"commonTop":["Hot flush","Erectile dysfunction","Flushing","Dysuria","Libido decreased"]}}}